https://www.humanexa.io/ 2026-06-07T18:40:19.264Z daily 1 https://www.humanexa.io/pricing 2026-06-07T18:40:19.264Z weekly 0.95 https://www.humanexa.io/insights 2026-06-07T18:40:19.264Z weekly 0.9 https://www.humanexa.io/signals 2026-06-07T18:40:19.264Z weekly 0.9 https://www.humanexa.io/companies 2026-06-07T18:40:19.264Z weekly 0.88 https://www.humanexa.io/regulatory 2026-06-07T18:40:19.264Z weekly 0.9 https://www.humanexa.io/strategy 2026-06-07T18:40:19.264Z weekly 0.9 https://www.humanexa.io/simulations 2026-06-07T18:40:19.264Z weekly 0.9 https://www.humanexa.io/workspace 2026-06-07T18:40:19.264Z weekly 0.9 https://www.humanexa.io/welcome 2026-06-07T18:40:19.264Z weekly 0.9 https://www.humanexa.io/newsletter 2026-06-07T18:40:19.264Z weekly 0.85 https://www.humanexa.io/privacy 2026-06-07T18:40:19.264Z yearly 0.3 https://www.humanexa.io/terms 2026-06-07T18:40:19.264Z yearly 0.3 https://www.humanexa.io/assets/astrazenecas-baxfendy-approval-a-strategic-shift-in-hypertension-treatment 2026-06-07T17:09:05.106Z weekly 0.88 https://www.humanexa.io/assets/eli-lillys-retatrutide-emerges-as-a-game-changer-in-obesity-treatment-landscape 2026-06-07T12:16:47.575Z weekly 0.88 https://www.humanexa.io/assets/strategic-engagement-essential-for-dual-prevention-pill-market-success 2026-06-07T10:39:05.419Z weekly 0.88 https://www.humanexa.io/assets/regulatory-approvals-reshape-competitive-landscape-in-cardiovascular-market 2026-06-07T08:00:22.165Z weekly 0.88 https://www.humanexa.io/assets/enhertus-potential-eu-approval-could-transform-her2-treatment-landscape 2026-06-07T06:01:46.037Z weekly 0.88 https://www.humanexa.io/assets/regulatory-acceptance-of-cosopt-pf-signals-competitive-shift-in-glaucoma-market 2026-06-07T06:01:37.909Z weekly 0.88 https://www.humanexa.io/assets/regulatory-approvals-reshape-competitive-landscape-in-neurology-markets 2026-06-07T04:13:16.289Z weekly 0.88 https://www.humanexa.io/assets/emerging-combination-therapies-and-targeted-approaches-in-liver-cancer-treatment 2026-06-07T03:07:34.148Z weekly 0.88 https://www.humanexa.io/assets/imfinzi-and-imjudos-pfs-improvement-signals-competitive-shift-in-liver-cancer 2026-06-07T03:07:32.122Z weekly 0.88 https://www.humanexa.io/assets/upsher-smiths-deflazacort-approval-strengthens-competitive-position-in-corticost 2026-06-06T18:54:34.014Z weekly 0.88 https://www.humanexa.io/assets/emerging-anesthetic-techniques-and-opioid-sparing-strategies-in-pain-management 2026-06-06T18:54:33.969Z weekly 0.88 https://www.humanexa.io/assets/aurobindo-pharmas-lamotrigine-approval-signals-market-disruption-in-antiepilepti 2026-06-06T18:53:58.340Z weekly 0.88 https://www.humanexa.io/assets/emerging-therapeutics-in-copd-tozorakimab-and-nmes-trials-signal-strategic-shift 2026-06-06T14:54:00.106Z weekly 0.88 https://www.humanexa.io/assets/tozorakimabs-phase-iii-success-positions-it-as-a-leader-in-copd-treatment 2026-06-06T14:54:00.053Z weekly 0.88 https://www.humanexa.io/assets/jiangsu-hansohs-dapagliflozin-submission-intensifies-sglt2-inhibitor-competition 2026-06-06T08:00:28.047Z weekly 0.88 https://www.humanexa.io/assets/regulatory-developments-enhance-competitive-landscape-for-tyvaso-in-pah-market 2026-06-06T08:00:21.796Z weekly 0.88 https://www.humanexa.io/assets/baxters-phenylephrine-approval-reshapes-vasopressor-market-dynamics 2026-06-06T06:39:00.474Z weekly 0.88 https://www.humanexa.io/assets/positive-phase-iii-results-for-efzimfotase-alfa-reshape-hypophosphatasia-landsca 2026-06-03T01:14:22.460Z weekly 0.88 https://www.humanexa.io/assets/breztris-unique-positioning-as-first-triple-therapy-in-asthma-market 2026-06-03T01:14:21.674Z weekly 0.88 https://www.humanexa.io/assets/navigating-new-fda-guidance-on-pregnancy-safety-studies-in-drug-development 2026-06-03T01:14:21.514Z weekly 0.88 https://www.humanexa.io/signals/lillys-retatrutide-shows-significant-weight-loss-and-pain-reduction-in-triumph-1 2026-06-07T06:01:53.253Z weekly 0.8 https://www.humanexa.io/signals/glenmark-pharmaceuticals-submits-supplemental-application-for-lamotrigine 2026-06-07T18:00:33.652Z weekly 0.8 https://www.humanexa.io/signals/fda-grants-ap-status-for-doxycycline-hyclate-supplement-by-impax-labs 2026-06-07T12:00:23.605Z weekly 0.8 https://www.humanexa.io/signals/south-african-hcps-support-dual-prevention-pill-but-highlight-key-challenges 2026-06-07T06:01:43.998Z weekly 0.8 https://www.humanexa.io/signals/fda-grants-ap-status-for-mesna-anda203364-submission-by-rising 2026-06-07T06:01:36.684Z weekly 0.8 https://www.humanexa.io/signals/fda-accepts-supplement-for-vabysmo-by-genentech 2026-06-07T06:01:28.328Z weekly 0.8 https://www.humanexa.io/signals/fda-approval-status-update-for-losartan-potassium-by-micro-labs 2026-06-07T00:00:24.901Z weekly 0.8 https://www.humanexa.io/signals/alembics-duloxetine-hydrochloride-supplement-receives-ap-status-from-fda 2026-06-07T00:00:16.620Z weekly 0.8 https://www.humanexa.io/signals/fda-approves-deflazacort-supplement-application-by-upsher-smith-labs 2026-06-06T18:00:40.324Z weekly 0.8 https://www.humanexa.io/signals/aurobindo-pharmas-lamotrigine-anda-submission-receives-ap-status 2026-06-06T18:00:31.331Z weekly 0.8 https://www.humanexa.io/signals/fda-approves-supplement-for-levetiracetam-by-chartwell-rx 2026-06-06T12:01:41.453Z weekly 0.8 https://www.humanexa.io/signals/fda-accepts-application-for-cosopt-pf-supplement-by-thea-pharma 2026-06-06T12:01:32.591Z weekly 0.8 https://www.humanexa.io/signals/fda-grants-approval-for-phenylephrine-hydrochloride-by-baxter-healthcare 2026-06-06T06:00:47.187Z weekly 0.8 https://www.humanexa.io/signals/fda-submission-update-for-ondansetron-hydrochloride-anda078127 2026-06-06T06:00:35.737Z weekly 0.8 https://www.humanexa.io/signals/fda-accepts-supplement-application-for-tyvaso-treprostinil 2026-06-06T00:00:51.990Z weekly 0.8 https://www.humanexa.io/signals/fda-submission-for-dapagliflozin-by-jiangsu-hansoh-pharma 2026-06-06T00:00:40.603Z weekly 0.8 https://www.humanexa.io/signals/comparative-study-of-spsipb-vs-thoracic-paravertebral-block-for-opioid-reduction 2026-06-02T03:09:28.046Z weekly 0.8 https://www.humanexa.io/signals/pilot-study-on-geniculate-artery-embolization-for-knee-osteoarthritis-initiated 2026-06-02T03:09:23.745Z weekly 0.8 https://www.humanexa.io/signals/imfinziimjudo-shows-significant-pfs-improvement-in-early-liver-cancer-trial 2026-06-02T03:09:20.953Z weekly 0.8 https://www.humanexa.io/signals/efzimfotase-alfa-shows-positive-phase-iii-results-in-hypophosphatasia 2026-06-02T03:09:15.835Z weekly 0.8 https://www.humanexa.io/signals/trial-on-pulmonary-artery-catheters-in-cardiac-surgery-aims-to-compare-recovery- 2026-06-02T03:01:35.313Z weekly 0.8 https://www.humanexa.io/signals/tapur-study-evaluates-targeted-therapies-in-advanced-cancer-with-genomic-variant 2026-06-02T03:01:32.508Z weekly 0.8 https://www.humanexa.io/signals/tozorakimab-achieves-primary-endpoints-in-phase-iii-trials-for-copd 2026-06-02T03:01:29.578Z weekly 0.8 https://www.humanexa.io/signals/enhertu-recommended-for-eu-approval-in-her2-metastatic-solid-tumours 2026-06-02T03:01:25.861Z weekly 0.8 https://www.humanexa.io/signals/zhuochuming-trial-evaluates-3te-vs-3prn-in-diabetic-macular-edema 2026-06-01T19:50:47.438Z weekly 0.8 https://www.humanexa.io/signals/study-on-nmes-for-functional-recovery-in-copd-and-pneumonia-patients 2026-06-01T19:50:43.736Z weekly 0.8 https://www.humanexa.io/signals/fda-issues-guidance-on-postapproval-pregnancy-safety-studies 2026-06-01T19:50:38.722Z weekly 0.8 https://www.humanexa.io/signals/astrazenecas-baxfendy-receives-us-approval-for-hypertension-as-first-in-class-tr 2026-06-01T19:50:35.739Z weekly 0.8 https://www.humanexa.io/signals/breztri-gains-us-approval-as-first-triple-therapy-for-asthma 2026-06-01T19:50:32.737Z weekly 0.8 https://www.humanexa.io/companies/undisclosed 2026-06-06T00:00:51.990Z weekly 0.82 https://www.humanexa.io/companies/roche 2026-06-07T06:01:36.684Z weekly 0.82 https://www.humanexa.io/companies/competitor 2026-06-06T00:00:51.990Z weekly 0.82 https://www.humanexa.io/companies/lilly 2026-06-07T12:00:23.605Z weekly 0.82 https://www.humanexa.io/companies/pfizer 2026-06-06T00:00:40.603Z weekly 0.82 https://www.humanexa.io/companies/merck 2026-06-06T00:00:40.603Z weekly 0.82 https://www.humanexa.io/companies/astrazeneca 2026-06-06T00:00:51.990Z weekly 0.82 https://www.humanexa.io/companies/competitivedynamicsintensify 2026-06-07T06:01:28.328Z weekly 0.82 https://www.humanexa.io/companies/elililly 2026-06-07T06:01:53.253Z weekly 0.82 https://www.humanexa.io/companies/lamotrigine 2026-06-07T18:00:33.652Z weekly 0.82 https://www.humanexa.io/companies/unitedtherapeutics 2026-06-06T00:00:51.990Z weekly 0.82 https://www.humanexa.io/companies/theapharma 2026-06-06T12:01:32.591Z weekly 0.82 https://www.humanexa.io/companies/changerinobesitytreatment 2026-06-07T06:01:53.253Z weekly 0.82 https://www.humanexa.io/companies/tyvaso 2026-06-06T00:00:51.990Z weekly 0.82 https://www.humanexa.io/companies/dapagliflozin 2026-06-06T00:00:40.603Z weekly 0.82 https://www.humanexa.io/companies/sglt2inhibitormarket 2026-06-06T00:00:40.603Z weekly 0.82 https://www.humanexa.io/companies/alexion 2026-06-02T03:09:15.835Z weekly 0.82 https://www.humanexa.io/companies/impaxlabs 2026-06-07T12:00:23.605Z weekly 0.82 https://www.humanexa.io/companies/doxycyclinehyclate 2026-06-07T12:00:23.605Z weekly 0.82 https://www.humanexa.io/companies/rising 2026-06-07T06:01:36.684Z weekly 0.82 https://www.humanexa.io/companies/mesna 2026-06-07T06:01:36.684Z weekly 0.82 https://www.humanexa.io/companies/vabysmo 2026-06-07T06:01:28.328Z weekly 0.82 https://www.humanexa.io/companies/anti-vegfmarket 2026-06-07T06:01:28.328Z weekly 0.82 https://www.humanexa.io/companies/cosoptpf 2026-06-06T12:01:32.591Z weekly 0.82 https://www.humanexa.io/companies/dualpreventionpill 2026-06-07T06:01:43.998Z weekly 0.82 https://www.humanexa.io/companies/hivpreventionmarket 2026-06-07T06:01:43.998Z weekly 0.82 https://www.humanexa.io/companies/southafricanhealthcareproviders 2026-06-07T06:01:43.998Z weekly 0.82 https://www.humanexa.io/companies/upshersmithlabs 2026-06-06T18:00:40.324Z weekly 0.82 https://www.humanexa.io/companies/microlabs 2026-06-07T00:00:24.901Z weekly 0.82 https://www.humanexa.io/companies/losartanpotassium 2026-06-07T00:00:24.901Z weekly 0.82 https://www.humanexa.io/companies/sparingstrategiesinpainmanagement 2026-06-02T03:09:28.046Z weekly 0.82 https://www.humanexa.io/companies/deflazacort 2026-06-06T18:00:40.324Z weekly 0.82 https://www.humanexa.io/companies/pharmassoc. 2026-06-06T06:00:35.737Z weekly 0.82 https://www.humanexa.io/companies/ondansetronhydrochloride 2026-06-06T06:00:35.737Z weekly 0.82 https://www.humanexa.io/companies/strategicimplicationsforhypertensionmarket 2026-06-01T19:50:35.739Z weekly 0.82 https://www.humanexa.io/companies/glenmarkpharmaceuticals 2026-06-07T18:00:33.652Z weekly 0.82 https://www.humanexa.io/companies/genentech 2026-06-07T06:01:28.328Z weekly 0.82 https://www.humanexa.io/companies/alembic 2026-06-07T00:00:16.620Z weekly 0.82 https://www.humanexa.io/companies/duloxetinehydrochloride 2026-06-07T00:00:16.620Z weekly 0.82 https://www.humanexa.io/companies/baxterhealthcare 2026-06-06T06:00:47.187Z weekly 0.82 https://www.humanexa.io/companies/phenylephrinehydrochloride 2026-06-06T06:00:47.187Z weekly 0.82 https://www.humanexa.io/companies/jiangsuhansohpharma 2026-06-06T00:00:40.603Z weekly 0.82 https://www.humanexa.io/companies/chartwellrx 2026-06-06T12:01:41.453Z weekly 0.82 https://www.humanexa.io/companies/aurobindopharma 2026-06-06T18:00:31.331Z weekly 0.82 https://www.humanexa.io/newsletter/3f84cd5a-99c2-49b3-b890-09f98fbce08c 2026-06-06T06:47:03.383Z monthly 0.75